- FDA Approves Motegrity (prucalopride) for Adults with Chronic Idiopathic Constipation (CIC)
- FDA Approves Herzuma (trastuzumab-pkrb), a Biosimilar to Herceptin
- FDA Approves Tolsura (SUBA®-itraconazole capsules) for the Treatment of Certain Fungal Infections
- FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
- FDA Approves Dextenza (dexamethasone ophthalmic insert) for the Treatment of Ocular Pain Following Ophthalmic Surgery
- FDA Approves Firdapse (amifampridine) for Lambert-Eaton Myasthenic Syndrome
- FDA Approves Xospata (gilteritinib) for Acute Myeloid Leukemia (AML) with a FLT3 Mutation
- FDA Approves Truxima (rituximab-abbs), a Biosimilar to Rituxan for Non-Hodgkin’s Lymphoma
- FDA Approves Vitrakvi (larotrectinib) for TRK Fusion Cancers
- FDA Approves The ACTpen for Actemra, A Single-Dose, Prefilled Autoinjector
- FDA Approves Daurismo (glasdegib) for Patients with Acute Myeloid Leukemia
- Genentech Announces FDA Grants Venclexta Accelerated Approval for People With Newly-Diagnosed Acute Myeloid Leukemia or Those Who Are Ineligible For Intensive Induction Chemotherapy
- FDA Approves Gamifant (emapalumab-lzsg) for Primary Hemophagocytic Lymphohistiocytosis
- FDA Approves Aemcolo (rifamycin) to Treat Travelers’ Diarrhea
- FDA Approves Adcetris (brentuximab vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas